BROOMFIELD, CO, May 16, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Pedro Ureña will present six month follow-up results from the first-in-human implantation of the Company's proprietary transcatheter aortic heart valve. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. In addition to Dr. Ureña's presentation, the Colibri TAVI system will be highlighted during a panel focused on emerging technologies. These presentations are taking place at EuroPCR 2013, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions taking place May 21-24 in Paris, France.
"These clinical results confirm the excellent pre-clinical performance observed from the Colibri TAVI system," stated Joseph B. Horn, Colibri's president and chief executive officer. "While the success to date of the first patient to receive our experimental TAVI system must, in part, be due to the clinical expertise of Dr. Ureña and the CEDIMAT center, we believe it is also a testament to the system's simplicity in design, which incorporates significant advantages over currently available TAVI systems. We look forward to continuing to monitor this patient's progress and expanding enrollment to additional individuals."
Dr. Pedro Ureña is the primary investigator of the Colibri clinical study and the director of the cardiovascular department at the Center of Advanced Medicine (CEDIMAT) in Santo Domingo, Dominican Republic. His podium presentation, titled "45-day Outcome of TAVI of the Lowest Profile Pre-Package and Sterilized Aortic Valve in the World" is part of the "Percutaneous Valve Implantation: New Valves and New Indications" session on Wednesday, May 22 beginning at 10:45am.
In addition, Dr. Bernard Chevalier, an attending cardiologist at the Institut Cardiovasculaire Paris-Sud and a member of the Colibri scientific advisory board will participate with industry leaders and highlight the Colibri TAVI system on an Emerging Technologies for Transcatheter Aortic Valve Therapies panel during EuroPCR. This panel is being held on Wednesday, May 22 from 09:45-11:45 in Room 242A.
For more information on the first-in-human implantation, please visit the Colibri Heart Valve booth (# M34) during the EuroPCR 2013 meeting, or review the Valve Implantation page of the Colibri Heart Valve website following the EuroPCR 2013 meeting.
About the Colibri Heart Valve and the Ready-to-Use Colibri TAVI System
Colibri Heart Valve, LLC is a privately held medical device company based in Broomfield, CO that researches and develops novel heart valve technologies. Colibri has developed a pre-mounted, pre-crimped, and pre-packaged, ready-for-use transcatheter aortic valve implantation (TAVI) device called the "Colibri TAVI System." TAVI is an important treatment option for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience, and reduced procedural costs. Colibri's advanced technology is a culmination of over 10 years of research and development by Colibri's founders, Dr. David Paniagua and Dr. R. David Fish into the tissue, valve design, frame, and delivery catheter. Colibri's unique tissue processing method produces extremely strong, durable, and biocompatible tissue. The proprietary tissue enables loading, crimping, and packaging of the Colibri valve at manufacture, making in-procedure valve rinsing and loading at time of use unnecessary. The "Colibri TAVI System" is designed to be shipped ready-for-use.
Colibri's corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. For more information, visit: www.colibrihv.com.